Biocept, Inc.

387 articles about Biocept, Inc.

• Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 03, 2021

  3/3/2021

  Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees.

• Study Shows Biocept’s Target Selector™ Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients

  2/16/2021

  Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects mutations in up to 50% of tissue biopsy specimens, from patients diagnosed with non-small cell lung cancer, that were deemed quantity not sufficient.

• Biocept Provides Update on COVID-19 Testing with More than 250,000 Samples Received

  2/3/2021

  Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its COVID-19 testing with more than 250,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory.

• Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  2/2/2021

  Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted inducement stock options to purchase an aggregate of 86,720 shares of its common stock to 5 new employees.

• Biocept Issues Letter to Stockholders - Jan 12, 2021

  1/12/2021

  Biocept, Inc., a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:

• Biocept to Present at H.C. Wainwright Virtual BioConnect Conference

  1/4/2021

  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable informat

• Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 31, 2020

  12/31/2020

  Biocept, Inc., a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announced that it has granted inducement stock options to purchase an aggregate of 83,120 shares of its common stock to 14 new employees.

• Biocept Enters into Laboratory Services Agreements with Two Southern California Regional Independent Physician Associations

  12/30/2020

  Expands physician and patient access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer

• Biocept Provides Business Update

  12/14/2020

  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve pat

• While The U.S. Faces Insufficient COVID-19 Testing Volume, EIR Healthcare Launches MedModLabs to Expand Access Immediately

  12/1/2020

  Healthcare design innovation firm known for its 'hospital in a box' solution expands modular offerings with new MedModLabs initiative, first rolling out in Philadelphia to help address Pennsylvania's poor testing rates

• Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central Nervous System

  11/20/2020

  Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing cerebrospinal fluid (CSF) samples in patients with primary lung or breast cancer with either brain or leptomeningeal disease

• Results from Study Using Biocept's Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®

  11/17/2020

  Biocept, Inc. announces that results from a prospective study using Target Selector™ testing to monitor disease progression in patients with metastatic breast cancer will be featured in a poster presentation at the virtual 2020 San Antonio Breast Cancer Symposium® on December 9, 2020.

• Biocept Reports Third Quarter 2020 Financial Results

  11/12/2020

  Biocept, Inc., a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, reports financial results for the three and nine months ended September 30, 2020 and provides an update on its business progress.

• Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received

  11/12/2020

  Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 100,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory. 

• Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells

  11/9/2020

  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has been awarded Hong Kong Patent No. 1188285 entitled, METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION.

• Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type

  11/5/2020

  Biocept further expands its patent estate for capturing and detecting target cells of interest, including CTCs

• Biocept to Release Third Quarter 2020 Financial Results and Host Investor Conference Call on November 12, 2020

  11/4/2020

  Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the three and nine months ended September 30, 2020 after the market closes on Thursday, November 12, 2020 . The Company will host a conf

• Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received

  10/29/2020

  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexi

• Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting

  10/1/2020

  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the upcoming presentation of results from a prospective study using its Target Selector™ testing of the cerebrospi

• Biocept Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations in Tissue, Blood and Cerebrospinal Fluid

  9/23/2020

  Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology for the field of oncology   [23-September-2020]   SAN DIEGO , Sept. 23, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable info